Retour sur lavenir.net
   VIOHALCO 17.660 € (+9,01 %)     UMICORE 21.700 € (+0,56 %)     CELYAD ONCOLOGY 0.231 € (-7,60 %)     VAN DE VELDE 30.000 € (+1,01 %)     GIMV 47.350 € (+0,21 %)     ASCENCIO 52.700 € (-1,13 %)     UCB 213.500 € (+0,66 %)     D'IETEREN GROUP 161.900 € (-2,06 %)     COLRUYT 38.920 € (+0,57 %)     ONTEX GROUP 2.090 € (-2,56 %)     KBC 132.950 € (-0,56 %)     TITAN S.A. 49.560 € (-0,56 %)     BPOST 1.178 € (-2,81 %)     BREDERODE 105.800 € (0,00 %)     ABO GROUP 4.000 € (-6,98 %)     AGEAS 74.950 € (-2,22 %)     HOME INVEST BE. 17.940 € (+0,22 %)     TINC 10.980 € (-0,36 %)     SYENSQO 79.050 € (+1,41 %)     GBL 74.550 € (+0,20 %)     KBC ANCORA 95.500 € (-0,31 %)     FAGRON 22.200 € (+1,14 %)     ECONOCOM GROUP 1.420 € (-0,35 %)     CMB.TECH 17.080 € (-1,39 %)     MONTEA 64.200 € (-0,31 %)     SIPEF 108.600 € (-0,91 %)     IMMOBEL 18.400 € (-0,81 %)     ONWARD MEDICAL 2.785 € (-4,13 %)     MELEXIS 69.850 € (+2,72 %)     TESSENDERLO 21.100 € (+3,43 %)     KINEPOLIS GROUP 50.800 € (+1,20 %)     EKOPAK 3.470 € (+0,29 %)     BARCO 7.495 € (+0,27 %)     CIE BOIS SAUVAGE 303.000 € (0,00 %)     HYLORIS 4.050 € (-3,57 %)     NYXOAH 1.250 € (-3,99 %)     SOLVAC NOM(RETAIL) 83.500 € (+1,83 %)     VASTNED 28.250 € (+0,18 %)     IBA 15.480 € (+0,13 %)     LOTUS BAKERIES 12 620.000 € (+1,12 %)     BEKAERT 38.350 € (+1,05 %)     XIOR 25.400 € (+0,20 %)     ELIA GROUP 120.400 € (+0,67 %)     RETAIL ESTATES 65.000 € (+0,15 %)     EVS 27.850 € (+2,01 %)     AB INBEV 68.340 € (+0,71 %)     FLUXYS BELGIUM D 22.200 € (0,00 %)     AGFA-GEVAERT 0.381 € (-0,39 %)     WAREHOUSES ESTATES 38.200 € (+2,41 %)     PROXIMUS 6.230 € (-2,50 %)     SOFINA 249.000 € (+1,06 %)     DECEUNINCK 2.500 € (+1,01 %)     JENSEN-GROUP 76.800 € (+2,13 %)     VGP 71.500 € (-0,28 %)     SOLVAY 25.360 € (+0,24 %)     SHURGARD 23.600 € (+0,43 %)     AEDIFICA 66.400 € (+0,91 %)     ORANGE BELGIUM 22.100 € (+0,45 %)     AZELIS GROUP 12.200 € (+1,92 %)     RECTICEL 12.720 € (+0,47 %)  
   CEGEDIM 11.000 € (+2,04 %)     L'OREAL 389.500 € (+1,49 %)     LVMH 401.950 € (-0,88 %)     STMICROELECTRONICS 46.600 € (+4,37 %)     KERING 232.000 € (+1,47 %)     DSM FIRMENICH AG 97.120 € (+2,95 %)     SBM OFFSHORE 36.340 € (+0,33 %)     ASML HOLDING 1 507.400 € (+1,76 %)     ASM INTERNATIONAL 860.800 € (+4,21 %)     ADYEN 903.000 € (+1,35 %)     ORANGE 14.395 € (-4,13 %)     ING GROEP N.V. 31.700 € (-1,48 %)     AUBAY 51.900 € (-1,14 %)     ESSILORLUXOTTICA 144.500 € (+2,30 %)     ENGIE 23.800 € (+0,46 %)     EURONEXT 158.400 € (-0,81 %)     ENOGIA 6.380 € (0,00 %)     PERNOD RICARD 60.640 € (+1,68 %)     ETHERO 0.920 € (+8,24 %)     ALTAREA 84.900 € (+0,24 %)     ELIOR GROUP 1.880 € (-3,04 %)     HEIJMANS KON 86.100 € (-3,26 %)     KAUFMAN ET BROAD 21.500 € (+1,90 %)     ALSTOM 15.270 € (+2,11 %)     BUREAU VERITAS 27.800 € (+2,39 %)     ALPES (COMPAGNIE) 17.700 € (-1,45 %)     SHELL PLC 41.010 € (+0,58 %)     TELEPERFORMANCE 70.100 € (+0,26 %)     BASIC-FIT 31.600 € (-1,86 %)     EUROCOMMERCIAL 27.250 € (+1,68 %)     TIKEHAU CAPITAL 16.220 € (-2,99 %)     DANONE 60.900 € (+1,06 %)     CSG 15.134 € (-0,51 %)     AEGON 7.832 € (-1,76 %)     74SOFTWARE 38.200 € (-0,78 %)     Vusion 133.000 € (+13,68 %)     HERMES INTL 1 355.000 € (+0,82 %)     PEUGEOT INVEST 51.400 € (-1,72 %)     PLANISWARE 23.550 € (-0,42 %)     BE SEMICONDUCTOR 191.900 € (+1,72 %)     SODEXO 57.400 € (+0,61 %)     BROADPEAK 2.210 € (+0,45 %)     BIOMERIEUX 73.250 € (+1,31 %)     ARKEMA 57.500 € (+2,04 %)     GTT 222.600 € (-0,62 %)     VALNEVA 2.831 € (-0,77 %)     GROUPE GUILLIN 20.300 € (-1,46 %)     AXA 43.910 € (-2,07 %)     EXOR NV 71.450 € (+0,35 %)     NEXITY 5.240 € (+3,25 %)     BENETEAU 5.260 € (+1,54 %)     UNILEVER 54.840 € (+1,22 %)     WORLDLINE 12.202 € (+1,68 %)     VOPAK 47.000 € (-1,51 %)     AMUNDI 92.750 € (-0,27 %)     SAINT GOBAIN 71.220 € (+1,60 %)     PHARMING GROUP 0.964 € (+3,92 %)     SANOFI 74.390 € (-0,27 %)     IMCD 95.180 € (+1,34 %)     ID LOGISTICS GROUP 324.500 € (+1,25 %)  
News Réglementées
07/09/2026 13:00

Clearway Capital rejects GZO's proposed composition agreement

Lemongrass Communications AG / Key word(s): Legal Matter
Clearway Capital rejects GZO's proposed composition agreement

07.09.2026 / 13:00 CET/CEST


Media Release

Clearway Capital urges creditors to reject GZO's proposed composition agreement

Zurich, 7 September 2026 Clearway Capital Partners ICAV (“Clearway”), a creditor of GZO AG Spital Wetzikon (“GZO”) leading the GZO Creditor Group, announces that it will vote against the composition agreement (Nachlassvertrag) to be put to creditors at the assembly expected in the second half of October 2026, and urges all creditors to do the same.

Creditors are being asked to approve the inferior of two offers. GZO’s plan, built around thurmed AG as strategic investor, delivers just CHF 70.1 million in cash, equal to 29.0% of claims. The headline recovery of 39.3–47.5% materially overstates the economic value being offered, as it relies on deferred and highly uncertain components: 10.3% is stretched over ten years without interest or security; a further 8.2% depends entirely on the outcome of GZO’s dispute with Steiner; and the additional EBITDA-linked payment cannot be quantified as it requires GZO to achieve an 8% operating margin, far above the 5.1% delivered in 2025. Clearway therefore assigns no value to the contingent components and only minimal present value to the deferred payment.

Creditors were denied the opportunity to compare the proposal against a materially better alternative, which was rejected by the company. On 29 July 2026, Infracore SA made a binding, fully financed offer of CHF 55 million in cash for GZO's real estate, payable upon confirmation of the composition agreement. Together with the CHF 96.5 million of cash and securities in GZO's audited 2025 accounts, Clearway estimates that this offer could have supported an immediate cash recovery of up to 60% - roughly double what creditors are now being asked to accept.

GZO terminated the Infracore offer on the basis of an assessment by its financial adviser PwC, which has not been shared with creditors. It is not the first time creditors have been asked to accept an advisor's conclusion in place of the underlying analysis. The bankruptcy comparison used to sell the current plan rests on a liquidation status that values GZO's entire fixed-asset base at CHF 12.0 million, and the hospital parcel itself at zero. A binding offer has now put a market price on that same real estate: CHF 55 million, more than four times the figure creditors were given.

Importantly for all creditors, this vote will not be decided by headcount alone. Under Article 305 SchKG, creditors holding just over one-third of total claims can block the agreement regardless of the number of heads voting in favor. At the September 2025 assembly, creditors representing some CHF 165 million of claims, approximately two-thirds of the total, were already aligned with Clearway's position. It is therefore of the utmost importance that as many creditors as possible participate in the assembly and cast their vote. Clearway is confident that the agreement will not pass in its current form and urges all creditors to participate, either in person or via proxy.

“Creditors are being asked to write off 70% of their claims to recapitalize a hospital in which they will receive no ownership, no security and no interest on the amounts still owed to them. At the same time, GZO rejected a substantially superior offer without giving creditors the opportunity to consider it,” said Gianluca Ferrari, founder of Clearway Capital.

“This is not a plan based on what GZO can afford to pay. It is a plan based on how little GZO believes creditors can be persuaded to accept,” he added.

Clearway will provide creditors with further updates ahead of the assembly, and practical assistance to any creditor wishing to vote against the agreement. Clearway is also evaluating all options at its disposal to protect creditor interests, including with regard to the decisions that have brought creditors to this point.

Creditors are invited to contact Clearway directly with questions regarding the exercise of their vote.

 

Contact for Media:
Lemongrass Communications AG

susanne.muehlemann@lemongrass.agency
+41 79 223 70 81

Contact for Investors:

contact@gzo-bondholder.ch

About Clearway Capital:

Clearway Capital Partners is an alternative investment fund that invests in special situations in Western European markets where seeks to unlock value through responsible ownership. With a focus on protecting investor rights and ensuring fair treatment of stakeholders, Clearway Capital actively advocates for transparent and equitable corporate practices.

 


Additional features:

File: Clearway_GZO_MM_07_09_26_E


End of Media Release
View original content: EQS News


2394934  07.09.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière